Deliver Your News to the World

Colopril Product Approved for International Sales Distribution


U.S. supplement manufacturer Pharmaxa Laboratories will make its much anticipated foray into the International marketplace very shortly. The nutraceutical manufacturer announced today that they received formal approval to begin International sales distribution of their Colopril product into foreign markets. Colopril has been generating national media attention since it was first reported that Colopril keeps the digestive tract from getting clogged up with mucus, toxins and metabolic waste, thereby improving one’s overall health.

“The approval and launch of this therapeutic breakthrough into overseas markets brings a new option to those millions of people that suffer from health issues related to toxic digestive tracts. We are extremely pleased to introduce Colopril to them. The product has already been widely used by consumers in North America. Today’s announcement is a unique and rare moment in the supplement industry as it shows that products like Colopril are going to make a huge positive impact on the health improvement of global consumers. We have already seen the positive reception that the product has garnered through the U.S. media and the response has been quite clear that Colopril is a product that works. We are bracing ourselves for this product to fly off the shelves” said Cathy Sheridan, Marketing Director North America.

One of the most talked about and sought after colon detoxifying products available today, Colopril™ has been scientifically formulated to promote gentle and effective internal cleansing and detoxification while eliminating parasites and dangerous toxins. Colopril’s precise combination of natural herbs and fibers will effectively balance and regulate your body for optimal health. The ground-breaking technology employed by the product is a blend of its’ active ingredients in a proprietary formula.

Pharmaxa Laboratories develops and markets nutraceutical products for the treatment of gastrointestinal issues. Hamada’s strategy is to in-license late-stage or marketed proprietary therapeutic supplements, complete any required development and regulatory submission of these products, and market them in the United States and Europe through the Company’s specialty sales and marketing team.

More complete detailed product information and directions of use can be found on


 body cleanse

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.